PD-1/PD-L1 blockade
PD-1/PD-L1 blockade refers to therapeutic inhibition of the Programmed cell death 1 (PD-1) receptor and its ligand CD274 molecule, an immune checkpoint axis that normally restrains T-cell activation.
PD-1/PD-L1 blockade refers to therapeutic inhibition of the Programmed cell death 1 (PD-1) receptor and its ligand CD274 molecule, an immune checkpoint axis that normally restrains T-cell activation. In physiology, this pathway helps maintain peripheral immune tolerance and limits excessive inflammation. In cancer and some inflammatory settings, however, PD-1/PD-L1 signaling can be co-opted to suppress cytotoxic T-cell function, promote T-cell dysfunction, and support immune escape.
As a biomedical target, PD-1/PD-L1 blockade is most widely associated with immunotherapy, but recent studies also examine its role in non-oncologic immune dysregulation, including sepsis. Across these contexts, blockade of the pathway is investigated as a way to restore immune homeostasis, enhance anti-tumor immunity, and counteract immunosuppression. Related mechanisms in the recent literature include PD-L1-mediated suppression of cytotoxic CD8+ T cells, PD-1-associated T-cell dysfunction in multiple myeloma, and checkpoint modulation alongside pathways such as signal transducer and activator of transcription 3 (STAT3) and β-catenin.
Where the papers sit
18 papers from the last 6 months study PD-1/PD-L1 blockade directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 4 observational · 2 human data · 11 preclinical · 1 unclassified
Themes 4 themes
-
Predicting Immunotherapy Response
Immune checkpoint treatment is moving toward biomarker-guided combinations and risk stratification across solid tumors. Response depth predicts progression risk, while Tregs, FN1+ macrophages, and lactate-linked HMGB1/HIF-1α signaling recur as mechanisms of immune escape or resistance. Peripheral T-cell subsets and blood-based kinase activity profiling are being developed to predict benefit in cervical cancer and NSCLC. Axitinib plus survivin vaccination illustrates efforts to make PD-1 therapy durable in renal carcinoma.
7 papers · 38.9%
-
PD-1 Signaling Beyond Cancer
PD-1/PD-L1 modulation is being extended from cancer to sepsis, cardiac homeostasis, and invasive mold infections. Moxibustion plus nivolumab improved immunosuppression in septic mice, potentially through CD44/JAK2/STAT3 signaling. Myeloid PD-1/PD-L1 signaling appears important for adult heart maintenance, while IFN-γ is being explored alongside anti-PD-1 in infection. Cancer studies point to β-catenin-driven ferroptosis resistance as another route to PD-L1-mediated immune evasion.
5 papers · 27.8%
-
PD-L1 Biology and Monitoring
PD-L1 biology is being connected to tumor immunity, immune regulation, and treatment monitoring across multiple cancers. Studies include PD-1/PD-L1 signaling in multiple myeloma and strategies for delivering PD-L1-targeting plasmids with copper complexes for chemoimmunotherapy. Regulatory T-cell dysfunction is emerging as a potential consequence of checkpoint inhibition rather than only a barrier to it. CRISPR/Cas12a detection of exosome RNA offers a route to monitor tumor progression, but therapeutic and monitoring approaches remain exploratory.
4 papers · 22.2%
-
Tumor Microenvironment Reprogramming
Local remodeling of immunosuppressive tumor microenvironments is being used to strengthen PD-1 blockade. TAM-targeting nano-immunotherapy seeks to reverse macrophage-driven suppression through biodegradable polymers, biomimetic vesicles, and flexible carriers. Intratumoral bicarbonate is being tested as an adjuvant to potentiate PD-1 blockade in hepatocellular carcinoma. The evidence remains primarily preclinical, with the key question being whether local reprogramming improves antitumor immunity in vivo.
2 papers · 11.1%
Papers
The 18 papers from the last 6 months that study PD-1/PD-L1 blockade directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Predicting Immunotherapy Response (7)
- Treg cells promote immunotherapy-induced immune evasion by restraining CD4 T cell control of MHC-I-deficient metastatic pancreatic cancer. Science immunology · 26 Jun 2026 PMID 42361199
- Sequential axitinib and survivin vaccination unlock curative PD-1 immunotherapy in renal carcinoma. Oncoimmunology · 25 Jun 2026 PMID 42343214
- Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study. Journal for immunotherapy of cancer · 24 Jun 2026 PMID 42342406
- EFHD2 drives lactate-mediated DNA damage repair and immunosuppression via HMGB1 and HIF-1α to confer radioresistance in colorectal cancer. Cell death & disease · 23 Jun 2026 PMID 42336814
- Using peripheral blood indicators and T cells subsets to evaluate the efficacy of immunotherapy for advanced and recurrent cervical cancer. Human vaccines & immunotherapeutics · 23 Jun 2026 PMID 42334275
- Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC. European journal of cancer (Oxford, England : 1990) · 12 Jun 2026 PMID 42284973
- FN1+ macrophages fuel aggressive sarcomatoid differentiation and immunotherapy refractory outcome in clear cell renal cell carcinoma. Oncogene · 5 Jun 2026 PMID 42249083
PD-1 Signaling Beyond Cancer (5)
- Moxibustion combined with anti-PD-1 antibodies improves immunosuppression in septic mice potentially through the PD-1/PD-L1 pathway. Immunologic research · 17 Jun 2026 PMID 42307810
- Combos New and Old Counter PD-(L)1 Resistance, Treat Rare Cancers. Cancer discovery · 4 Jun 2026 PMID 42240229
- Myeloid-derived immunosuppressive PD-1/PD-L1 signaling is essential to maintain adult heart homeostasis. American journal of physiology. Heart and circulatory physiology · 1 Jun 2026 PMID 42223114
- Druggable β-catenin palmitoyl-switch coordinates immune evasion via immunogenic ferroptosis resistance and PD-L1-mediated immunosuppression. Cell reports. Medicine · 28 May 2026 PMID 42208545
- Emerging evidence for anti-PD-1 and IFN-γ as adjunctive immunotherapy in invasive mold infections. mBio · 22 May 2026 PMID 42171361
PD-L1 Biology and Monitoring (4)
- Checkpoint inhibitors create rogue regulatory T cells. The Journal of clinical investigation · 1 Jul 2026 PMID 42383349
- Programmed cell death protein 1 (PD-1) / programmed cell death ligand 1 (PD-L1) in multiple myeloma. Journal of the Egyptian National Cancer Institute · 17 Jun 2026 PMID 42307688
- Multifunctional copper complex-mediated self-blocking plasmid delivery of PD-L1 for tumor chemoimmunotherapy. Colloids and surfaces. B, Biointerfaces · 3 Jun 2026 PMID 42235197
- An Exosome RNA In Situ Detection Platform Based on a Regulated CRISPR/Cas12a Activity System and Its Application in Tumor Progression Monitoring and Therapeutic Efficacy Evaluation. Analytical chemistry · 3 Jun 2026 PMID 42231680
Tumor Microenvironment Reprogramming (2)
- Nano-Immunotherapy Targeting TAMs: Precisely Regulating TAMs to Reverse Immunosuppressive TME. International journal of nanomedicine · 23 Jun 2026 PMID 42333283
- Intratumoral bicarbonate functions as an adjuvant to potentiate PD-1 blockade in hepatocellular carcinoma. Oncogene · 4 Jun 2026 PMID 42243329
By study type
Observational studies and case reports (4)
- Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study. Journal for immunotherapy of cancer · 24 Jun 2026 PMID 42342406
- Using peripheral blood indicators and T cells subsets to evaluate the efficacy of immunotherapy for advanced and recurrent cervical cancer. Human vaccines & immunotherapeutics · 23 Jun 2026 PMID 42334275
- Programmed cell death protein 1 (PD-1) / programmed cell death ligand 1 (PD-L1) in multiple myeloma. Journal of the Egyptian National Cancer Institute · 17 Jun 2026 PMID 42307688
- Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC. European journal of cancer (Oxford, England : 1990) · 12 Jun 2026 PMID 42284973
Human data, design not indexed (2)
- Combos New and Old Counter PD-(L)1 Resistance, Treat Rare Cancers. Cancer discovery · 4 Jun 2026 PMID 42240229
- Emerging evidence for anti-PD-1 and IFN-γ as adjunctive immunotherapy in invasive mold infections. mBio · 22 May 2026 PMID 42171361
Preclinical: animal, cell and lab studies (11)
- Checkpoint inhibitors create rogue regulatory T cells. The Journal of clinical investigation · 1 Jul 2026 PMID 42383349
- Treg cells promote immunotherapy-induced immune evasion by restraining CD4 T cell control of MHC-I-deficient metastatic pancreatic cancer. Science immunology · 26 Jun 2026 PMID 42361199
- Sequential axitinib and survivin vaccination unlock curative PD-1 immunotherapy in renal carcinoma. Oncoimmunology · 25 Jun 2026 PMID 42343214
- Nano-Immunotherapy Targeting TAMs: Precisely Regulating TAMs to Reverse Immunosuppressive TME. International journal of nanomedicine · 23 Jun 2026 PMID 42333283
- Moxibustion combined with anti-PD-1 antibodies improves immunosuppression in septic mice potentially through the PD-1/PD-L1 pathway. Immunologic research · 17 Jun 2026 PMID 42307810
- FN1+ macrophages fuel aggressive sarcomatoid differentiation and immunotherapy refractory outcome in clear cell renal cell carcinoma. Oncogene · 5 Jun 2026 PMID 42249083
- Intratumoral bicarbonate functions as an adjuvant to potentiate PD-1 blockade in hepatocellular carcinoma. Oncogene · 4 Jun 2026 PMID 42243329
- Multifunctional copper complex-mediated self-blocking plasmid delivery of PD-L1 for tumor chemoimmunotherapy. Colloids and surfaces. B, Biointerfaces · 3 Jun 2026 PMID 42235197
- An Exosome RNA In Situ Detection Platform Based on a Regulated CRISPR/Cas12a Activity System and Its Application in Tumor Progression Monitoring and Therapeutic Efficacy Evaluation. Analytical chemistry · 3 Jun 2026 PMID 42231680
- Myeloid-derived immunosuppressive PD-1/PD-L1 signaling is essential to maintain adult heart homeostasis. American journal of physiology. Heart and circulatory physiology · 1 Jun 2026 PMID 42223114
- Druggable β-catenin palmitoyl-switch coordinates immune evasion via immunogenic ferroptosis resistance and PD-L1-mediated immunosuppression. Cell reports. Medicine · 28 May 2026 PMID 42208545
Unclassified: not yet indexed with MeSH (1)
- EFHD2 drives lactate-mediated DNA damage repair and immunosuppression via HMGB1 and HIF-1α to confer radioresistance in colorectal cancer. Cell death & disease · 23 Jun 2026 PMID 42336814
Written from 18 PubMed abstracts, each one listed by PMID above. Published: 2026-06-18. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.